Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.

This letter to the editor published in the journal Leukemia & Lymphoma discusses a retrospective analysis conducted by the authors on the outcomes of patients with FLT3-mutated acute myeloid leukemia (AML) who were treated with idarubicin and cytarabine, with or without midostaurin. The study found that the addition of midostaurin did not lead to improved response rates or survival compared to treatment without midostaurin. However, patients who underwent allogeneic stem cell transplantation had better outcomes. The authors concluded that while midostaurin was safe and well-tolerated, it did not provide additional benefits in this real-world population. The study had limitations, such as the lack of a placebo arm and the absence of survival data, and the authors suggest further investigation is needed to determine the true benefit of midostaurin in combination with idarubicin or other anthracyclines. [Extracted from the article]